7QFA image
Entry Detail
PDB ID:
7QFA
Title:
Monoclinic crystal structure of PTG CBM21 in complex with beta-cyclodextrin
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-12-05
Release Date:
2022-11-02
Method Details:
Experimental Method:
Resolution:
2.00 Å
R-Value Free:
0.21
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
I 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Protein phosphatase 1 regulatory subunit 3C
Mutations:First residue S derives from the expression tag
Chain IDs:A, B, C
Chain Length:134
Number of Molecules:3
Biological Source:Homo sapiens
Ligand Molecules
Peptide-like Molecules
PRD_900012
Primary Citation
Molecular architecture of the glycogen- committed PP1/PTG holoenzyme.
Nat Commun 13 6199 6199 (2022)
PMID: 36261419 DOI: 10.1038/s41467-022-33693-z

Abstact

The delicate alternation between glycogen synthesis and degradation is governed by the interplay between key regulatory enzymes altering the activity of glycogen synthase and phosphorylase. Among these, the PP1 phosphatase promotes glycogenesis while inhibiting glycogenolysis. PP1 is, however, a master regulator of a variety of cellular processes, being conveniently directed to each of them by scaffolding subunits. PTG, Protein Targeting to Glycogen, addresses PP1 action to glycogen granules. In Lafora disease, the most aggressive pediatric epilepsy, genetic alterations leading to PTG accumulation cause the deposition of insoluble polyglucosans in neurons. Here, we report the crystallographic structure of the ternary complex PP1/PTG/carbohydrate. We further refine the mechanism of the PTG-mediated PP1 recruitment to glycogen by identifying i) an unusual combination of recruitment sites, ii) their contributions to the overall binding affinity, and iii) the conformational heterogeneity of this complex by in solution SAXS analyses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures